Evidence suggests that testosterone may contribute to the development of CRC through multiple pathways, and serum free testosterone levels, together with carcinoembryonic antigen, are expected to serve as a potential biomarker for CRC (Roshan et al., 2016). The gene discussed is CEACAM5; the disease is colorectal carcinoma.